Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0HJNAG
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
HER-E-46
|
|||||
| Synonyms |
HER-E-46
Click to Show/Hide
|
|||||
| Organization |
NJ BIO INC
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
8.3
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
WO2024020536A1+HER-E-44+payload
|
Payload Info | ||||
| Linker Name |
Mc-Gly-Gly-Phe-Gly
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 35.06 pM | High HER2 expression (HER2 +++) | ||
| Method Description |
A Cell line test on SKBR-3
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||